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A REVIEW OF OPIOID REPLACEMENT THERAPY WITH METHADONE OR 
BUPRENORPHINE ON NEURAL DEVELOPMENT IN THE NEWBORN 
MAHAM JAVAID 
ABSTRACT 
 Opioid replacement therapy with methadone or buprenorphine has been 
recommended for managing opioid dependence during pregnancy. Although 
opioid replacement therapy decreases harmful consequences from maternal illicit 
drug seeking behaviors, the effects of methadone and buprenorphine on 
neurogenesis and myelination in the developing fetus have not been thoroughly 
reviewed. Methadone and buprenorphine may alter newborn neurobehavioral 
functions by impairing neurogenesis and changing the developmental pattern of 
myelination. This review found that therapeutic doses of methadone and 
buprenorphine disturb both neurogenesis and myelination in rodents. Methadone 
and buprenorphine may alter newborn neurobehavioral functions by impairing 
neurogenesis and changing the developmental pattern of myelination. However, 
further studies are required to bridge the gap in the understanding between 
changes in neural development and abnormalities in neurobehavioral function in 
the newborn. 
  
   
v 
 
TABLE OF CONTENTS 
 
TITLE……………………………………………………………………………………...i 
COPYRIGHT PAGE………………………………………………………………….....ii 
READER APPROVAL PAGE………………………………………………………….iii 
TABLE OF CONTENTS ....................................................................................... v 
LIST OF FIGURES.......................................................................................................... vi 
LIST OF ABBREVIATIONS ........................................................................................... vii 
INTRODUCTION .................................................................................................. 1 
AIMS ................................................................................................................... 10 
LITERATURE REVIEW ...................................................................................... 10 
CONCLUSION .................................................................................................... 44 
REFERENCES ................................................................................................... 46 
CURRICULUM VITAE ........................................................................................ 51 
 
  
   
vi 
 
LIST OF FIGURES 
 
 
Figure Title Page 
1 Figure 1 8 
2 Figure 2 9 
3 Figure 3 9 
4 Figure 4 11 
5 Figure 5 13 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
Figure 6 
Figure 7 
Figure 8 
Figure 9 
Figure 10 
Figure 11 
Figure 12 
Figure 13 
Figure 14 
Figure 15 
Figure 16 
Figure 17 
Figure 18 
14 
15 
16 
17 
18 
22 
24 
28 
31 
32 
35 
36 
37 
  
   
vii 
 
LIST OF ABBREVIATIONS 
 
ATP ................................................................................... Adenosine triphosphate 
BrdU ........................................................................................ Bromodeoxyuridine 
Ca .............................................................................................................. Calcium 
cAMP ................................................................. Cyclic adenosine monophosphate 
DAPI ....................................................................... 4’, 6-Diamidino-2-phenylindole 
G-protein .............................. Guanine nucleotide binding protein monophosphate 
GABA ........................................................................... Gamma amino butyric acid 
GDP ............................................................................ Guanosine monophosphate 
GTP .................................................................................. Guanosine triphosphate 
K ............................................................................................................. Potassium 
 
 
 
 
   
1 
 
 
INTRODUCTION 
 
According to the 2013 National Survey on Drug Use and Health, 5.4% of 
pregnant women reported illicit drug use within the past month, including heroin 
and prescription opioid analgesics, such as morphine, hydromorphone, codeine, 
hydrocodone, oxycodone and fentanyl (1). Opioid abuse during pregnancy has 
been linked to obstetric complications, such as intrauterine growth restriction, 
neural tube defect, placental dysfunction, premature labor, and spontaneous 
abortion as well as neonatal abstinence syndrome following birth (2). The 
percentage of pregnant women abusing opioids specifically has not been 
determined however, and adverse human pregnancy outcomes from maternal 
opioid abuse remain poorly understood. Opioid replacement therapy with 
methadone or buprenorphine, long acting opioid analogues, has been 
recommended for opioid dependence during pregnancy to minimize symptoms of 
withdrawal in the fetus, safeguard placental function, and decrease harmful 
consequences from maternal illicit drug seeking behaviors, such as poor nutrition, 
infection, and exposure to crime and violence (2). However, both methadone and 
buprenorphine readily transverse the human placenta (3) which raises the concern 
for chronically administered exogenous opioids interfering with endogenous opioid 
systems in the developing fetal central nervous system and ultimately, disrupting 
neural development. 
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Mechanisms of Opioid Receptor Signal Transduction 
 
Previous studies have demonstrated that opioids are involved in modulating 
central nervous system activity, including perception of pain, euphoria, dysphoria, 
respiration, and function of the hypothalamic-pituitary axis by selectively binding 
and activating opioid receptors following birth (4). Classically, opioid receptors are 
a group of G-protein coupled receptors specifically associated with inhibitory 
heterotrimeric G-proteins and are widely distributed throughout the mammalian 
central nervous system. Upon activation, opioid receptors undergo a 
conformational change and induce the inhibitory G-protein alpha subunits to 
exchange GDP for GTP. The GTP-bound inhibitory G-protein alpha subunit 
dissociates from the G-protein beta-gamma dimer and inhibits adenylyl cyclase 
from generating cAMP from ATP. Decreased availability of cAMP leads to 
decreased activity of cAMP-dependent protein kinase, modifying a variety of 
downstream intracellular processes. The G-protein beta-gamma dimer binds 
directly to calcium channels and can decrease voltage dependent channel opening 
in neurons; inward calcium current decreases which dampens neurotransmitter 
release. The G-protein beta-gamma dimer can also bind directly to inwardly 
rectifying potassium channels, leading to an increased inward potassium current 
and thereby membrane hyperpolarization (4). 
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Distribution of Opioid Receptors in the Adult Mammalian  
Central Nervous System 
 
To date, three opioid receptor subtypes have been discriminated – mu (µ), 
delta (δ) and kappa (κ) – and are widely distributed throughout the adult 
mammalian central and peripheral nervous systems. Mu opioid receptors 
demonstrate high affinity for the endogenous opioid peptide beta-endorphin, 
morphine (full agonist), methadone (full agonist), and buprenorphine (partial 
agonist), among other exogenous opioids (4). Mu opioid receptors are 
constitutively expressed and modulate analgesia within the amygdala, substantia 
nigra, periaqueductal gray, rostroventral medulla, and substantia gelatinosa of 
Rolando in the dorsal horn. Mu opioid receptors have also been identified within 
the cerebral cortex, thalamus, striate nucleus, interpeduncular nucleus, and 
superior and inferior colliculi (5). In contrast to mu opioid receptors, delta opioid 
receptors bind endogenous enkephalins and are frequently found within the 
cytoplasm of neurons contributing to the olfactory bulb, substantia gelatinosa of 
Rolando, amygdala, striate nucleus, and prefrontal cortex (6, 7) as well as 
specialized mechanosensory end organs and axons surrounding hair follicles (8); 
cell surface expression of delta opioid receptors has been suggested to occur via 
regulated secretion (6). 
The roles of mu opioid receptors and delta opioid receptors in modulating 
perception of pain within the spinal cord have been elucidated (9). Activation of mu 
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opioid receptors, and to a lesser degree delta opioid receptors, expressed on C 
fiber synaptic terminals in the substantia gelatinosa of Rolando, inhibits their 
release of excitatory Substance P onto second order sensory neurons, disrupting 
transmission of thermally and mechanically induced nociceptive input. Activation 
of mu opioid receptors and delta opioid receptors also inhibits second order 
sensory neurons directly by increasing potassium conductance post-synaptically, 
leading to membrane hyperpolarization and reduced excitability and thereby 
attenuating the perception of pain (9). Delta opioid receptors have also been 
identified on the presynaptic terminals of GABA (gamma-amino butyric acid) 
releasing interneurons synapsing onto glutamatergic principal cells within the 
hippocampus and are implicated in learning and memory (10). 
Furthermore, mu opioid receptors and kappa opioid receptors modulate the 
mesolimbic dopamine system, a reward pathway associated with substance 
dependence and addiction, although not fully understood, in which dopaminergic 
neurons from the ventral tegmental area of the midbrain project into the nucleus 
accumbens of the forebrain. GABAergic neurons express mu opioid receptors and 
continuously inhibit dopaminergic neurons in the ventral tegmental area. Activation 
of mu opioid receptors prevents GABAergic neurons from inhibiting dopamine 
release from dopaminergic neurons in the ventral tegmental area and nucleus 
accumbens. Dopamine released from ventral tegmental area neurons onto the 
nucleus accumbens contributes to generating positive reinforcement (4). 
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However, activation of kappa opioid receptors with dynorphins, a family of 
endogenous opioid peptides, induces dysphoria, a state of emotional distress, by 
depressing dopamine release from dopaminergic neurons in the ventral tegmental 
area onto the nucleus accumbens and prefrontal cortex. Kappa opioid receptors 
are also expressed within the striate nucleus on the presynaptic terminals of 
dopaminergic neurons, hippocampus, amygdala, dorsal raphe nucleus and 
substantia nigra (11). Interestingly, chronic opioid and cocaine exposures have 
been shown to increase the release of dynorphin within the striate nucleus and 
decrease the number of dopamine receptors within the caudate putamen in mice, 
potentially serving as a safeguard against dopamine-induced neurotoxicity from 
drug abuse (12). 
 
Expression Timeline for Opioid Receptors in the Mammalian 
Central Nervous System during Prenatal Development 
 
During prenatal development, opioid receptors and endogenous opioid 
peptides are expressed within the central nervous system, and growing evidence 
supports a role for the endogenous opioid system in the developing central 
nervous system. Rius et al. first detected mu opioid receptors and kappa opioid 
receptors on embryonic days 12.5 and 14.5, respectively, in rodents, and observed 
a gradual increase in their expression and anatomic distribution throughout the 
prenatal period, developing an expression profile comparable to the adult by 
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embryonic day 17.5; delta opioid receptors were first detected following birth on 
postnatal day 1 (13). However, beta-endorphin, met-enkephalin, and dynorphin 
were first detected on embryonic day 11.5, preceding the expression of opioid 
receptors. Levels of met-enkephalin and dynorphin increased continuously 
throughout the prenatal period, whereas beta-endorphin peaked on embryonic day 
18.5 and subsequently diminished to levels previously observed on embryonic day 
14.5 until birth. Rising levels of beta-endorphin, met-enkephalin and dynorphin 
observed from embryonic day 11.5 through 18.5, in addition to increasing 
expression of mu opioid receptors and kappa opioid receptors, paralleled an 
increase in brain mass, possibly implicating the opioid receptor system in central 
neurodevelopment (13). 
 
Overview of Methadone and Buprenorphine 
 
Opioid replacement therapy with methadone or buprenorphine has been 
recommended for managing opioid dependence during pregnancy. The United 
States Food and Drug Administration classifies both methadone and 
buprenorphine as Pregnancy Category C controlled substances, meaning that 
human controlled studies are insufficient; however, the potential benefits may 
justify use in pregnant women. To date, a randomized controlled trial comparing 
opioid replacement therapy with opioid detoxification therapy during pregnancy on 
newborn outcomes has not been published. In fact, opioid detoxification therapy 
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during pregnancy presents a risk for relapse and premature labor, and is not 
regarded as best practice. Methadone maintenance therapy is the current 
recommended standard of care for treating opioid dependence in pregnant women 
(2). 
Methadone (Figure 1) is a synthetic opioid which is highly selective for and 
fully agonizes the mu opioid receptor not unlike morphine (Figure 2), and is used 
to achieve harm reduction from illicit drug use and relieve symptoms of opioid 
withdrawal. However, overdose on methadone can result in respiratory 
depression, circulatory collapse and death. In methadone maintenance therapy, 
opioid dependent individuals report each day as outpatients for a strictly controlled 
oral dose of methadone and urine toxicology screening for illicit substances. 
Participation in methadone maintenance therapy on a daily basis offers pregnant 
women suffering from opioid dependence opportunities for regular and frequent 
contact with health care providers and education which both have been shown to 
limit drug seeking behaviors and enhance antenatal care (2). 
Buprenorphine (Figure 3) is a semi-synthetic opioid derived from 
paramorphine and has a long duration of action at mu opioid receptors and kappa 
opioid receptors. Buprenorphine is a partial agonist at the mu opioid receptor, and 
an antagonist at the kappa opioid receptor and the delta opioid receptor. 
Buprenorphine is often prepared as a combination product with naloxone, an 
opioid receptor antagonist, in a sublingual film or tablet marketed as Suboxone in 
order to deter intravenous abuse (15). Although naloxone administered 
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sublingually has a relatively low bioavailability, the National Institute of Drug Abuse 
recommends that pregnant women with opioid dependence receive buprenorphine 
monotherapy to avoid exposing the developing fetus to naloxone. As a reasonable 
alternative to methadone, buprenorphine is provided once a week generally in an 
outpatient office-based setting by a qualified physician in order to achieve harm 
reduction from illicit drug use and limit symptoms of opioid withdrawal (14). 
Buprenorphine demonstrates a lower maximal efficacy upon binding the mu opioid 
receptor compared to methadone and exhibits a ceiling effect with higher doses 
which decreases the risk of overdose in opioid dependent individuals compared to 
methadone (15). 
 
Figure 1. The two dimensional structure and three 
dimensional conformer for methadone. Note the T-shape 
configuration of the three dimensional conformer common 
to opioids (16). 
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Figure 2. The two dimensional structure and three 
dimensional conformer for morphine. Note the T-shape 
configuration of the three dimensional conformer common 
to opioids (17). 
 
 
Figure 3. The two dimensional structure and three dimensional 
conformer for buprenorphine. Note the T-shape configuration 
of the three dimensional conformer common to opioids (18). 
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AIMS 
 
 The purpose of this paper is two-fold: to describe the implications of opioid 
replacement therapy with methadone or buprenorphine on neurogenesis during 
prenatal development and to review the current understanding of opioid 
replacement therapy with methadone or buprenorphine during pregnancy on 
neonatal and early childhood neurobehavioral outcomes. 
 
LITERATURE REVIEW 
 
 
 During prenatal development, opioid receptors and endogenous opioid 
peptides are expressed within the central nervous system, and growing evidence 
supports a role for the endogenous opioid system in neurogenesis, myelination 
and neurotransmitter pathways (20, 22, 25, and 26). Mu opioid receptors have 
been identified on neural progenitor cells within the developing central nervous 
system in mice (19). Willner et al. have demonstrated that acute exposure of neural 
progenitor cells to increasing concentrations of morphine, a full mu opioid receptor 
agonist, significantly decreased the incorporation of bromodeoxyuridine (BrdU) 
(Figure 4), a marker for cell proliferation, in neural progenitor cells (20).  
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Figure 4. Increasing concentrations of 
morphine reduced the proliferation of neural 
progenitor cells in vitro. Neural progenitor cells 
were obtained from the cerebral cortices of 
mouse embryos at day 14 of gestation. 4’, 6-
diamidino-2-phenylindole (DAPI) was used to 
visualize nuclear DNA (adapted from Willner et 
al., 2015 (20)). 
 
Willner et al. have also demonstrated that acute exposure of neural 
progenitor cells to increasing concentrations of morphine significantly increased 
the activity of caspase-3, a biomarker for apoptosis, using in vitro mouse models 
(Figure 5) (20). Furthermore, they have demonstrated a significant increase in the 
incorporation of TUJ1, a marker for neuron specific class III beta-tubulin, in the 
number of bromodeoxyuridine stained cells with increasing concentrations of 
morphine in vitro (20). Additionally, they reported a significant decrease in the 
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incorporation of nestin, a marker for neural stem cells, in the number of 
bromodeoxyuridine stained cells with increasing concentrations of morphine in 
vitro (Figure 6) (20).  
These findings suggest that an acute exposure to morphine, and possibly 
other full mu opioid receptor agonists such as methadone, may induce proliferating 
neural progenitor cells to prematurely undergo apoptosis or differentiate into 
neurons during embryonic development and upset the concerted, transient, and 
vulnerable sequence of events necessary for normal central nervous system 
development. Furthermore, the addition of naloxone, an opioid receptor 
antagonist, to neural progenitor cells exposed to morphine, significantly increased 
the incorporation of bromodeoxyuridine and the expression of nestin, and 
decreased caspase-3 activity compared to neural progenitor cells exposed only to 
morphine, supporting that morphine was producing effects by activating the mu 
opioid receptor (20). Although these findings support a role for the mu opioid 
receptor in mediating the proliferation, renewal, and apoptosis of neural progenitor 
cells, the results from in vitro studies using mice cannot be definitively extrapolated 
to in vivo studies or to humans.  
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Figure 5. Increasing concentrations of morphine 
increased caspase-3 activity of neural 
progenitor cells in vitro. Neural progenitor cells 
were obtained from the cerebral cortices of 
mouse embryos at day 14 of gestation. 4’, 6-
diamidino-2-phenylindole (DAPI) was used to 
visualize nuclear DNA (adapted from Willner et 
al., 2015 (20)). 
   
14 
 
 
Figure 6. Increasing concentrations of morphine 
decreased the number of neural stem cells and 
increased the number of developing neurons in vitro. 
Neural stem cells were obtained from the cerebral 
cortices of mouse embryos at day 14 of gestation 
(adapted from Willner et al., 2015 (20)). 
  
Furthermore, the findings from Willner et al. are somewhat limited because 
prenatal morphine exposure may not be comparable to prenatal methadone 
exposure. Although morphine (Figure 1) and methadone (Figure 2) are 
buprenorphine (Figure 3) are mu opioid receptor agonists, they differ in chemical 
composition, three dimensional conformation, and some interacting residues of the 
mu opioid receptor in mice (Figure 8) (21). The binding of morphine may induce 
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the mu opioid receptor to undergo a different conformational change by interacting 
with a different combination of residues (Figure 8), potentially activating a different 
cellular signaling pathway and leading to a different effect than the binding of 
methadone or buprenorphine. However, no significant correlations have been 
demonstrated between the binding affinity or ligand efficacy and the interaction of 
ligands with specific residues of the mu opioid receptor (21). For example, 
naloxone and nalbuphine share 9 residues in the binding pocket of the mu opioid 
receptor (Figure 7); however, naloxone acts as a mu opioid receptor antagonist 
and nalbuphine acts as a partial mu opioid receptor agonist (21).  
 
Figure 7. An interior view of the murine mu opioid 
receptor binding pocket. Naloxone (green) has 
been observed to interact with 10 residues and 
nalbuphine (red) has been observed to interact 
with 11 residues in the binding pocket of the mu 
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opioid receptor. Naloxone and nalbuphine interact 
with nine of the same residues in the binding 
pocket of the mu opioid receptor (21). 
 
 
Figure 8. Interacting residues within the binding pocket of the murine 
mu opioid receptor for methadone and morphine. Methadone and 
morphine have been observed to interact with seven and eight 
residues, respectively, in the binding pocket of the mu opioid receptor. 
Methadone and morphine share six residues in the binding pocket of 
the mu opioid receptor (adapted from Cui et al., 2013 (21)). 
 
The effect of chronic prenatal exposure to methadone on neurogenesis in 
the developing central nervous system has not been comprehensively studied 
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using whole animal models. However, Nassogne et al. studied the structural 
organization of the cerebral cortex in mice chronically exposed to methadone in 
utero (22). They administered 40 mg/kg of methadone daily to pregnant mice by 
subcutaneous injection from day 8 of gestation through day 18 of gestation, and 
reported no significant difference in brain mass between mouse pups with prenatal 
methadone exposure and controls assessed on embryonic day 17 and postnatal 
days 0, 11 and 40 (22). They also reported no significant difference in the migration 
of neurons within the cerebral cortex assessed on postnatal day 11 (Figure 9) and 
no significant difference in the laminar structure of the cerebral cortex assessed 
on postnatal day 40 (Figure 10) between mouse pups with chronic prenatal 
methadone exposure and controls administered an equal volume of saline solution 
(22). 
 
Figure 9. Cerebral cortex of mouse pups on postnatal day 11 
comparing equal volume of saline solution to chronic prenatal 
methadone exposure. No significant difference detected in the 
migration of neurons within the cerebral cortex. Cell nuclei 
   
18 
 
labeled with bromodeoxyuridine (adapted from Nassogne et 
al., 1998 (22)). 
 
 
Figure 10. Cerebral cortex of mice on postnatal day 40 comparing chronic 
prenatal methadone exposure to equal volume of saline solution. No significant 
difference detected in the horizontal lamination of neurons and the radial 
alignment of neurons. Sections prepared using cresyl violet stain (adapted from 
Nassogne et al., 1998 (22)). 
 
Nassogne et al. exposed mouse pups prenatally to supratherapeutic doses 
of methadone, specifically 40 times greater than the recommended dose for 
managing opioid dependence in humans (22). Although Nassogne et al. did not 
identify any abnormalities in the cerebral cortex of mice with repeated prenatal 
methadone exposure (22), their findings do not necessarily demonstrate that 
methadone does not interfere with the formation of the cerebral cortex. During 
prenatal development, cells within the cerebral cortex begin expressing mu opioid 
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receptors and kappa opioid receptors (13). Methadone binds to mu opioid 
receptors with a higher affinity than kappa opioid receptors (23); more mu opioid 
receptors than kappa opioid receptors are occupied when exposed to a therapeutic 
dose of methadone. However, a supratherapeutic dose of methadone may 
increase the occupancy and activation of kappa opioid receptors in addition to 
activating mu opioid receptors. Activated kappa opioid receptors produce several 
effects which have been observed to counteract and offset the effects of activated 
mu opioid receptors (24). By activating kappa opioid receptors, Nassogne et al. 
may have offset the effects of activated mu opioid receptors, producing no overall 
detectable effect on the structure of the cerebral cortex. In contrast, a therapeutic 
dose of methadone may have disturbed neurogenesis and the formation of the 
cerebral cortex by activating mu opioid receptors unopposed.  
Furthermore, the effect of chronic prenatal exposure to methadone on the 
function of oligodendrocytes, particularly myelination in the developing central 
nervous system, is not fully understood. Mu opioid receptors and kappa opioid 
receptors have been identified near the nucleus and widely throughout the 
cytoplasm, respectively, in oligodendrocyte progenitor cells harvested from mouse 
pups 0 through 2 days of age, and grown in vitro, whereas delta opioid receptors 
appear to be absent (Figure 11) (25). Knapp et al. exposed enriched 
oligodendrocytes to 1 micromolar PL017, a selective mu opioid receptor agonist, 
and bromodeoxyuridine, a marker for cell proliferation, for 27 hours, and reported 
a significant increase in the number of cells staining with both O4, a marker for 
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early oligodendrocyte progenitor cells, and bromodeoxyuridine compared to the 
control, enriched oligodendrocytes which were not treated with PL017 (25). They 
also exposed enriched oligodendrocytes to 3 micromolar naloxone in addition to 1 
micromolar PL017, and found no significant change in the number of cells staining 
with both O4 and bromodeoxyuridine, indicating that PL017 increased the 
proliferation of oligodendrocyte progenitor cells by activating the mu opioid 
receptor (25). Knapp et al. also exposed enriched oligodendrocytes to 1 
micromolar PL017 for 96 hours and bromodeoxyuridine for the last 22 hours, and 
reported no significant change in the number of oligodendrocyte progenitor cells 
staining with bromodeoxyuridine compared to the control, enriched 
oligodendrocytes treated with both PL017 and naloxone (25). Furthermore, Knapp 
et al. exposed enriched oligodendrocytes to 1 micromolar U50488, a selective 
kappa opioid receptor agonist, and bromodeoxyuridine for 27 hours, and reported 
no significant change in the number of oligodendrocyte progenitor cells staining 
with bromodeoxyuridine compared to the control, enriched oligodendrocytes 
treated with both U50488 and nor-binaltorphimine, a selective kappa opioid 
receptor antagonist (25). They also exposed enriched oligodendrocytes to 1 
micromolar U50488 and bromodeoxyuridine for 48 hours, and reported no 
significant change in the number of oligodendrocyte progenitor cells staining with 
bromodeoxyuridine compared to the control, enriched oligodendrocytes treated 
with both U50488 and nor-binaltorphimine; however, enriched oligodendrocytes 
exposed to 1 micromolar U50488 for 48 hours demonstrated a significant increase 
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in size, from 1660 micrometers2 to 2368 micrometers2 (25). Although these 
findings support a role for the mu opioid receptor in mediating the proliferation of 
oligodendrocyte progenitor cells and the kappa opioid receptor in mediating the 
growth of oligodendrocyte progenitor cells, the results from in vitro studies using 
mice cannot be definitively extrapolated to in vivo studies or to humans.  
 
Figure 11. Oligodendrocytes were immunostained, following 
six days of enrichment, for delta opioid receptors, kappa 
opioid receptors, and mu opioid receptors. Polyclonal 
antibodies and nickel-diaminobenzidine were used. Delta 
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opioid receptors were not detected. Kappa opioid receptors 
were detected typically two days following mu opioid 
receptors (adapted from Knapp et al., 1998 (25)). 
 
Furthermore, Vestal-Laborde et al. administered 9 mg/kg of methadone 
daily to pregnant rats via subcutaneous osmotic mini-pumps for 28 days starting 
from day 7 of gestation and reported significant increases in myelin basic protein, 
myelin oligodendrocyte glycoprotein, and proteolipid proteins in rat pups 11 days 
of age and 19 days of age with both prenatal and postnatal methadone exposure 
compared to controls (26). They reported no significant difference in the number 
of axons with 4 or less loosely wrapped myelin sheaths and the number of axons 
with more than 4 uncompact myelin sheaths between rat pups 16 days of age with 
both prenatal and postnatal methadone exposure and controls (26). They found a 
significant increase in the number of axons with compact myelin sheaths in the 
corpus callosum of rat pups 16 days of age with both prenatal and postnatal 
methadone exposure compared to the controls (Figure 12), indicating a premature 
increase in the number of mature axons; however, the g ratio, calculated as the 
axon diameter divided by the myelinated fiber diameter, for axons with compact 
myelin sheaths was not significantly different between groups (26). 
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Figure 12. Comparing compact myelin sheaths in the corpus 
callosum of rat pups 16 days of age with both prenatal and 
postnatal methadone exposure to equal volume saline solution 
control. A significant increase in the number of axons with 
compact myelin sheaths was noted with both prenatal and 
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postnatal methadone exposure. Sections stained using uranyl 
acetate and lead citrate, and photographed under 5000x 
magnification with electron microscopy (adapted from Vestal-
Laborde et al., 2014 (26)). 
 
Vestal-Laborde et al. have also demonstrated that exposure of 
oligodendrocyte progenitor cells, harvested from rat pups 3 days of age, to 
methadone significantly increased the incorporation of thymidine labeled with 
tritium, and therefore cell proliferation (26). Vestal-Laborde et al. further 
demonstrated that exposure of preoligodendrocytes, harvested from rat pups 9 
days of age, to methadone significantly increased myelin basic protein and myelin 
oligodendrocyte glycoprotein, markers of highly mature oligodendrocytes, 
suggesting methadone exposure may induce preoligodendrocytes to prematurely 
differentiate (26).  
Chronic prenatal exposure to methadone may interfere with endogenous 
opioid systems which are potentially involved in myelin formation in the developing 
central nervous system. Exposure to exogenous opioids may alter the function of 
oligodendrocytes and the developmental pattern of myelination in the prenatal 
brain and spinal cord. The findings of Vestal-Laborde et al. suggest that chronic 
exposure to methadone may induce oligodendrocyte progenitor cells to undergo 
proliferation and prematurely myelinate axons during prenatal development and 
upset the concerted, transient, and vulnerable sequence of events necessary for 
normal central nervous system development.  
In vivo studies also suggest that chronic prenatal exposure to methadone 
may also interfere with neurotransmitter pathways (27). Guo et al. administered 9 
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mg/kg of methadone daily to pregnant rats via subcutaneous osmotic mini-pumps 
from day 8 of gestation through delivery, and found significant decreases in 
acetylcholine in the striatum of rat pups 4 days of age with prenatal methadone 
exposure compared to controls (27). However, Guo et al. did not quantify the 
number of cholinergic neurons in the striatum of rat pups with prenatal methadone 
exposure for comparison to control values, and did not determine the extent of 
acetylcholine production in the striatum of rat pups with prenatal methadone 
exposure for comparison to control values.  
Furthermore, Robinson administered 9 mg/kg of methadone daily to 
pregnant rats via subcutaneous osmotic mini-pumps for 28 days starting from day 
7 of gestation, and found significant decreases in acetylcholine in the striatum of 
rat pups 4 days of age with prenatal methadone exposure and rat pups 4 days of 
age with both prenatal and postnatal methadone exposure compared to controls 
(28), consistent with findings from Guo et al. However, no significant decreases in 
acetylcholine in the striatum of rat pups 10 days of age and 21 days of age with 
either prenatal methadone exposure or prenatal and postnatal methadone 
exposure were noted in comparison to controls (28). 
Robinson measured acetylcholine in the striatum of rat pups with prenatal 
and postnatal methadone exposure because rats are born at a stage of 
development comparable to the end of the second trimester in humans (32). 
Interestingly, cholinergic neurons of the striatum do not express mu opioid 
receptors and kappa opioid receptors, and only express delta opioid receptors 
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following birth (28). The pattern of opioid receptor expression on cholinergic 
neurons of the striatum suggests that decreases in acetylcholine in rat pups with 
prenatal methadone exposure were not due to methadone directly binding onto 
cholinergic neurons but rather acting indirectly via neurons communicating with 
cholinergic neurons. 
The effect of chronic prenatal exposure to buprenorphine on neurogenesis 
in the developing central nervous system has been examined using whole animal 
models (29). Wu et al. administered 1.0 mg/kg of buprenorphine daily to pregnant 
mice via intraperitoneal injection from days 7 through 21 of gestation and 
demonstrated a significant decrease in body mass, brain mass, and brain-to-body 
mass ratio in mouse pups with chronic prenatal exposure to buprenorphine 
compared to controls (29). Wu et al. also found a significant increase in the 
immobility time during both the forced swimming test and the tail suspension test 
in mouse pups with chronic prenatal exposure to buprenorphine compared to 
controls (Figure 13A and Figure 13B) (29). The forced swimming test and the tail 
suspension test are commonly used for assessing depression in rodents (29). Wu 
et al. demonstrated that mouse pups with chronic prenatal exposure to 
buprenorphine had a significant increase in depression-like behaviors compared 
to controls (29). However, these findings are somewhat limited because Wu et al. 
exposed mouse pups prenatally to a supratherapeutic dose of buprenorphine, 
greater than the recommended dose of buprenorphine daily for managing opioid 
dependence in humans. 
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Figure 13. (A) Comparing immobility times of males 
and females with prenatal 1.0 mg/kg/day of 
buprenorphine exposure to 0 mg/kg/day of 
buprenorphine controls for the forced swimming test 
(sample size of 10 mouse pups per group). Mouse 
pups were subjected to the forced swimming test for 
five minutes. A significant increase in the immobility 
time for the forced swimming test was detected in 
mouse pups (males and females) with prenatal 
exposure to buprenorphine compared to controls. (B) 
Comparing immobility times of males and females with 
prenatal 1.0 mg/kg/day of buprenorphine exposure to 
0 mg/kg/day of buprenorphine controls for the tail 
suspension test (sample size of 10 mouse pups per 
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group). Mouse pups were subjected to the tail 
suspension test for six minutes. A significant increase 
in the immobility time for the tail suspension test was 
detected in mouse pups (males and females) with 
prenatal exposure to buprenorphine compared to 
controls (adapted from Wu et al., 2014 (29)). 
 
Mouse pups with chronic prenatal exposure to buprenorphine also 
demonstrated a significant reduction in the number of neuronal cells staining 
positive for NeuN (Figure 14A), a nuclear protein exclusive to neurons, and the 
quantity of MAP-2, a microtubule associated protein exclusive to neurons, and 
class 3 beta-tubulin, a microtubule exclusive to neurons, in the prefrontal cortex, 
compared to controls (Figure 14B) (29). Mouse pups with chronic prenatal 
exposure to buprenorphine also demonstrated a significant reduction in the 
quantity of proteins related to neural stem cells, such as nestin, sex determining 
region Y box 2, and Kruppel-like factor 4, and proteins related to neural precursor 
cells and immature neurons, such as doublecortin (Figure 15) (29). These findings 
suggest that chronic exposure to buprenorphine may limit the proliferation and 
renewal of neural progenitor cells during prenatal development, and potentially 
interfere with the vulnerable sequence of events necessary for normal central 
nervous system development. Mu opioid receptors and kappa opioid receptors 
have been identified on neural progenitor cells within the developing central 
nervous system in mice (16). Buprenorphine binds to mu opioid receptors with a 
higher affinity than to kappa opioid receptors in vitro (30), such that more mu opioid 
receptors than kappa opioid receptors will be occupied when exposed to a 
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therapeutic dose of buprenorphine. However, a supratherapeutic dose of 
buprenorphine may increase the occupancy and limit the activation of kappa opioid 
receptors by endogenous opioid peptides in addition to activating mu opioid 
receptors. Activated kappa opioid receptors produce several effects which have 
been observed to counteract and offset the effects of activated mu opioid receptors 
in mice (24). By exposing mouse pups chronically to supratherapeutic doses of 
buprenorphine from days 7 through 21 of gestation, Wu et al. may have limited the 
activation of kappa opioid receptors and consequently, the counteracting effects 
of kappa opioid receptors on the effects of activated mu opioid receptors. Wu et al. 
may have observed a more significant decrease in neurogenesis than may be 
expected from therapeutic doses of buprenorphine as recommended to manage 
opioid dependence during pregnancy. 
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Figure 14. (A) Decreased population of neurons in the 
prefrontal cortex of male and female mouse pups with 
prenatal exposure to buprenorphine compared to controls. 
Neurons stained for NeuN. (B) Western blot of protein content 
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in the prefrontal cortex of mouse pups with prenatal exposure 
to buprenorphine compared to controls; sample size for each 
group was 8 mouse pups. A significant decrease in NeuN, 
MAP-2, and class III beta-tubulin was detected in mouse pups 
with prenatal exposure to buprenorphine compared to 
controls. No significant change was detected in GFAP (glial 
fibrillary acidic protein which is commonly expressed in 
astrocytes), and GADPH, glyceraldehyde-3-phosphate 
dehydrogenase, between mouse pups with prenatal exposure 
to buprenorphine compared to controls (adapted from Wu et 
al., 2014 (29)). 
 
 
Figure 15. Western blot of protein content in 
the prefrontal cortex of mouse pups with 
prenatal exposure to buprenorphine 
compared to controls; sample size for each 
group was 8 mouse pups. A significant 
decrease in nestin, SOX2, KLF4, 
doublecortin, and cyclin D1 was detected in 
mouse pups with prenatal exposure to 
buprenorphine compared to controls. No 
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significant change was detected in GADPH 
(glyceraldehyde-3-phosphate 
dehydrogenase) between mouse pups with 
prenatal exposure to buprenorphine 
compared to controls (adapted from Wu et al., 
2014 (29)). 
 
Furthermore, the effect of chronic prenatal exposure to buprenorphine on 
the function of oligodendrocytes, particularly myelination, is not fully understood. 
Sanchez et al. administered 0.3 mg/kg or 1.0 mg/kg of buprenorphine daily to 
pregnant rats via subcutaneous osmotic mini-pumps for 28 days starting from day 
7 of gestation (33). They reported significant increases in all four major isoforms 
of myelin basic protein, consisting of 14.0, 17.0, 18.5, and 21.5 kDa isoforms, in 
rat pups 12 days of age (beginning of brain myelination), 19 days of age (peak of 
brain myelination), and 26 days of age (end of brain myelination) with both prenatal 
and postnatal 0.3 mg/kg of buprenorphine exposure compared to the controls 
(Figure 16A, Figure 16B, Figure 16C) (33). Myelin basic protein is a marker of 
highly mature oligodendrocytes (31). Sanchez et al. exposed rat pups to 
buprenorphine both prenatally and postnatally because rats are born at a stage of 
development comparable to the end of the second trimester in humans; the early 
postnatal period in rats is comparable to the third trimester in humans (32). A dose 
of 0.3 mg/kg of buprenorphine once a day in rodents is comparable to the dose 
recommended for managing opioid dependence in humans (33).  
They also reported significant decreases in all four major isoforms of myelin 
basic protein in rat pups 12 days of age with both prenatal and postnatal 1.0 mg/kg 
of buprenorphine exposure compared to the controls (Figure 16A) (33).  However, 
   
33 
 
they reported no significant difference in any of the four major isoforms of myelin 
basic protein in rat pups 19 days of age and 26 days of age with both prenatal and 
postnatal 1.0 mg/kg of buprenorphine exposure compared to the controls (Figure 
16B and Figure 16C) (33). A dose of 1.0 mg/kg of buprenorphine once a day in 
rodents is comparable to an overexposure of buprenorphine in humans (33).
Furthermore, Sanchez et al. reported no significant difference in the number 
of myelinated axons in the corpus callosum of rat pups 26 days of age with both 
prenatal and postnatal 0.3 mg/kg of buprenorphine exposure compared to controls 
(33). They reported a significant decrease in the number of myelinated axons in 
the corpus callosum of rat pups 26 days of age with both prenatal and postnatal 
1.0 mg/kg of buprenorphine exposure compared to controls (Figure 17) (33). They 
also reported a significant increase in the number of large diameter myelinated 
fibers and a significant decrease in the thickness of the myelin sheath of large 
diameter myelinated fibers in rats 26 days of age with prenatal and postnatal 
exposure to either 0.3 mg/kg of buprenorphine or 1.0 mg/kg of buprenorphine daily 
(Figure 18) (33). However, they reported no significant change in the number of 
unmyelinated axons in the corpus callosum of rat pups 26 days of age with prenatal 
and postnatal exposure to 0.3 mg/kg of buprenorphine or 1.0 mg/kg of 
buprenorphine compared to the controls (33). 
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Figure 16. (A) Western blot of the four major isoforms of myelin basic protein, 
consisting of 14.0, 17.0, 18.5, and 21.5 kDa isoforms, in the whole brain of rat pups 
12 days of age. A significant increase in all four major isoforms of myelin basic 
protein was detected in rat pups with prenatal and postnatal exposure to 0.3 mg/kg 
of buprenorphine compared to the controls (c). A significant decrease in all four 
major isoforms of myelin basic protein was detected in rat pups with prenatal and 
postnatal exposure to 1.0 mg/kg of buprenorphine compared to the controls (c). 
(B) Western blot of the four major isoforms of myelin basic protein, consisting of 
14.0, 17.0, 18.5, and 21.5 kDa isoforms, in the whole brain of rat pups 19 days of 
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age. A significant increase in all four major isoforms of myelin basic protein was 
detected in rat pups with prenatal and postnatal exposure to 0.3 mg/kg of 
buprenorphine compared to the controls (c). No significant difference in any of the 
four major isoforms of myelin basic protein was detected in rat pups with prenatal 
and postnatal exposure to 1.0 mg/kg of buprenorphine compared to the controls 
(C) Western blot of the four major isoforms of myelin basic protein, consisting of 
14.0, 17.0, 18.5, and 21.5 kDa isoforms, in the whole brain of rat pups 26 days of 
age. A significant increase in all four major isoforms of myelin basic protein was 
detected in rat pups with prenatal and postnatal exposure to 0.3 mg/kg of 
buprenorphine compared to the controls (c). No significant difference in any of the 
four major isoforms of myelin basic protein was detected in rat pups with prenatal 
and postnatal exposure to 1.0 mg/kg of buprenorphine compared to the controls 
(c). Beta-actin was used as a loading control (adapted from Sanchez et al., 2008 
(33)). 
 
 
Figure 17. Myelinated axons in the corpus callosum of rat pups 26 days of age. 
Stained using toluidine blue and photographed at 1000 times magnification. A 
significant decrease myelinated axons was detected in rat pups with prenatal and 
postnatal exposure to 1.0 mg/kg of buprenorphine compared to the controls and 
0.3 mg/kg of buprenorphine (adapted from Sanchez et al., 2008 (33)). 
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Figure 18. Electron micrographs of 
myelinated axons in the corpus callosum of 
rat pups 26 days of age. Stained using 
uranyl acetate and lead citrate, and 
photographed at 1200 times magnification 
(adapted from Sanchez et al., 2008 (33)). 
 
Sanchez et al. also reported a significant decrease in myelin associated 
glycoprotein in the corpus callosum of rat pups 12 days of age with prenatal and 
postnatal 1.0 mg/kg buprenorphine exposure compared to controls and 0.3 mg/kg 
of buprenorphine exposure (33). They also reported a significant increase in myelin 
 37 
associated glycoprotein in the corpus callosum of rat pups 26 days of age with 
prenatal and postnatal 0.3 mg/kg or 1.0 mg/kg of buprenorphine exposure 
compared to controls; myelin associated glycoprotein was significantly greater in 
rat pups with 0.3 mg/kg of buprenorphine exposure compared to 1.0 mg/kg of 
buprenorphine exposure (33).  
Chronic prenatal exposure to therapeutic doses of buprenorphine may 
interfere with endogenous opioid systems which are potentially involved in myelin 
formation in the developing central nervous system. Myelin basic protein, a marker 
of highly mature oligodendrocytes, was significantly increased with prenatal and 
postnatal exposure to 0.3 mg/kg of buprenorphine (33). These findings suggest 
that chronic exposure to therapeutic levels of buprenorphine may induce cells 
within the oligodendrocyte lineage to prematurely differentiate and change axon 
growth and the developmental pattern of myelination, potentially upsetting the 
vulnerable sequence of events necessary for normal central nervous system 
development.  
In vivo studies suggest that chronic prenatal exposure to buprenorphine 
may also interfere with neurotransmitter pathways (28). Robinson administered 0.3 
mg/kg buprenorphine daily to pregnant rats via subcutaneous osmotic mini-pumps 
for 28 days starting from day 7 of gestation, and found significant decreases in 
acetylcholine in the striatum of rat pups 4 days of age with prenatal buprenorphine 
exposure (28). Rat pups 4 days of age with prenatal and postnatal 0.3 mg/kg/day 
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buprenorphine exposure also demonstrated decreases in striatal acetylcholine 
although non-significant (28). 
Robinson measured acetylcholine in the striatum of rat pups with prenatal 
and postnatal methadone or buprenorphine exposure because rats are born at a 
stage of development comparable to the end of the second trimester in humans 
(32). Cholinergic neurons of the striatum do not express mu and kappa opioid 
receptors, and only express delta opioid receptors following birth (28). The pattern 
of opioid receptor expression on cholinergic neurons of the striatum suggests that 
decreases in acetylcholine in rat pups with prenatal buprenorphine exposure were 
not due to buprenorphine directly binding onto cholinergic neurons but rather 
acting indirectly via neurons communicating with cholinergic neurons. 
Interestingly, rat pups 4 days of age with prenatal and postnatal 0.3 mg/kg/day 
buprenorphine exposure did not demonstrate a significant decrease in striatal 
acetylcholine which requires further study of the mechanisms involved. 
Methadone maintenance therapy and buprenorphine monotherapy are 
effective options for managing opioid dependence during pregnancy, minimizing 
the harmful consequences from maternal drug seeking behaviors, and improving 
antenatal care (2). However, both methadone and buprenorphine readily 
transverse the human placenta (3) which raises the concern for chronically 
administered exogenous opioids interfering with endogenous opioid systems in the 
vulnerable fetal central nervous system and translating into poor central nervous 
system outcomes later. In rodent models, methadone has been demonstrated to 
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bind at least twice up to 14 times as many neurons in the developing central 
nervous system of the fetus than in the adult central nervous system of the mother; 
however, this study’s investigators did not determine whether methadone was 
binding to pharmacologically active opioid receptors in the fetus (34). Children with 
a history of repeated exposure to therapeutic levels of methadone or 
buprenorphine in utero may however require routine follow-up and monitoring 
throughout infancy and/ or early childhood.  
McGlone et al. reported that infants six months of age born to women with 
opioid dependence and maintained on methadone (with polysubstance 
exposures), scored lower than healthy drug-free controls in all developmental 
areas assessed by Griffiths Mental Development Scales, including locomotor 
skills, personal and social skills, hearing and language skills, eye and hand 
coordination, and performance, after adjusting for maternal cigarette smoking and 
alcohol consumption (35). Furthermore, newborn infants exposed to methadone in 
utero have a decreased occipital frontal head circumference at birth compared with 
healthy drug-free controls matched for age, demographic, and maternal cigarette 
smoking, and by six months of age, differences in occipital frontal head 
circumference between infants exposed to methadone in utero and healthy drug-
free controls were no longer significant (35). In addition to a decreased occipital 
frontal head circumference at birth, several newborn infants exposed to 
methadone in utero also demonstrated strabismus and nystagmus (35). In 
contrast, Baldacchino et al. performed a meta-analysis using five case-control 
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studies and found no significant difference in neurobehavioral outcomes for both 
infants and preschool aged children repeatedly exposed to opioids only (mothers 
excluded for polysubstance use) in utero compared to healthy drug-free controls 
by assessing general cognition, executive function, memory, language, 
psychomotor skills, and personal and social skills (36). Interestingly, both infants 
and preschool aged children repeatedly exposed to opioids in utero performed 
poorer than healthy drug-free controls on all neurobehavioral testing (36). 
However, these findings are somewhat limited and may be unreliable because 
Baldacchino et al. only analyzed a small number of studies with a small sample 
size which reduces the chance of detecting a true effect on neurobehavioral 
outcomes for both infants and preschool aged children from repeated exposure to 
opioids in utero. Furthermore, Baldacchino et al. did not specifically examine 
neurobehavioral outcomes for both infants and preschool aged children with 
respect to repeated methadone versus buprenorphine exposure in utero. 
Previous studies have rarely examined a history of repeated exposure to 
methadone or buprenorphine in utero on neonatal and/ or early childhood 
neurodevelopmental and behavioral outcomes, and the findings, which have been 
published, are inconsistent. However, neonatal withdrawal syndrome has been 
well documented and described (37). Neonatal withdrawal syndrome is a complex 
multi-system disorder and refers to a group of signs and symptoms of withdrawal 
from gestational opioid exposure in newborn infants, including, but not limited to, 
high-pitched crying, hyperactivity, tremors, seizures, hypersensitivity to stimuli, 
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excessive sucking, poor feeding and rapid breathing (37). Newborn infants with a 
history of chronic in utero exposure to buprenorphine had lower incidence of 
neonatal withdrawal syndrome, required considerably less morphine to manage 
withdrawal symptoms, and had shorter length of hospital stay compared to 
newborn infants with a history of chronic in utero exposure to methadone (37). 
Neurobehavioral outcomes for the newborn infant with a history of chronic 
in utero exposure to either methadone or buprenorphine are not well understood.  
Coyle et al. examined neurobehavioral outcomes in a double blind study for 
newborn infants, specifically birth through postnatal day 30, with regard to a history 
of repeated in utero exposure to methadone versus buprenorphine, and found that 
newborn infants exposed to buprenorphine scored significantly lower on average 
than newborn infants exposed to methadone in excitability, arousal, and 
hypertonia, using the Neonatal Intensive Care Unit Network Neurobehavioral 
Scale; high scores for excitability, arousal, and hypertonia indicate dysregulated 
neurobehavioral functioning (38). The Neonatal Intensive Care Unit Network 
Neurobehavioral Scale provides a comprehensive assessment of central nervous 
system development and integrity in vulnerable infants with prenatal substance 
exposure (38). They also reported that newborn infants exposed to buprenorphine 
demonstrated fewer signs of stress-abstinence and required less handling to 
achieve a quiet-alert state (better self-regulation) compared to newborn infants 
exposed to methadone; however, neurobehavioral outcomes improved in newborn 
infants exposed to either methadone or buprenorphine by postnatal day 30 (38). 
 42 
In addition, Coyle et al. corroborated that newborn infants chronically exposed to 
buprenorphine in utero had lower incidence of neonatal withdrawal syndrome, had 
shorter length of hospital stay to manage neonatal withdrawal syndrome, and 
required less morphine to treat withdrawal symptoms compared to newborn infants 
chronically exposed to methadone in utero (38). Newborn infants with a history of 
repeated in utero exposure to buprenorphine demonstrated less adverse 
neurobehavioral outcomes and severity of withdrawal than their methadone 
counterparts (38) which suggests that buprenorphine may be the better option for 
managing opioid dependence during pregnancy with regard to minimizing harm to 
the developing central nervous system in the embryo or fetus. 
Although Coyle et al.’s findings suggest that opioid replacement therapy 
with buprenorphine during pregnancy minimizes withdrawal symptoms and 
adverse neurobehavioral outcomes, such as excitability, arousal and hypertonia, 
in the newborn infant compared with methadone, they are limited by confounding 
factors, such as possibly unreported maternal use of alcohol, tobacco, and illegal 
substances during pregnancy, and a small sample size. Furthermore, Jones et al. 
previously performed a double blind study comparing neurobehavioral outcomes 
for newborn infants, birth through postnatal day 14, with respect to a history of 
repeated in utero exposure to methadone versus buprenorphine (39). Jones et 
al.reported that newborn infants with a history of chronic in utero exposure to 
methadone scored lower than their buprenorphine counterparts in excitability and 
arousal, using the Neonatal Intensive Care Unit Network Neurobehavioral Scales 
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(39), which contradicts Coyle et al.’s recent findings. The inconsistencies between 
these two independent studies may be due to different maternal histories of 
substance use, unreported maternal use of alcohol, tobacco, and illegal 
substances during pregnancy, and timing of exposure to methadone or 
buprenorphine during prenatal development. 
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CONCLUSION 
 
 Increasing evidence supports a crucial role for endogenous opioid systems 
in prenatal brain and spinal cord development; repeated exposure to methadone 
or buprenorphine may interfere with endogenous opioid systems, potentially 
compromising neurogenesis, myelination, and neurotransmitter pathways in the 
developing central nervous system, and impairing neurobehavioral functions. This 
literature review found that the effect of chronic prenatal exposure to therapeutic 
doses of methadone on the proliferation, differentiation, and apoptosis of neural 
progenitor cells has not been recently studied although methadone maintenance 
therapy is the current recommended standard of care for treating opioid 
dependence in pregnant women. Interestingly, the effect of chronic prenatal 
exposure to buprenorphine on neurogenesis has not been studied using 
comparable therapeutic doses of buprenorphine in mice. Furthermore, 
buprenorphine has not been administered to mouse pups during the early 
postnatal period which is comparable to the third trimester in humans, in addition 
to the prenatal period, in order to model human gestation in its entirety. The 
findings from chronic prenatal only exposure to supratherapeutic doses of 
buprenorphine in mice may not be translatable to chronic prenatal exposure to 
therapeutic doses of buprenorphine in humans. Additionally, chronic exposure to 
therapeutic doses of methadone has been shown to increase the proliferation of 
oligodendrocyte progenitors, induce preoligodendrocytes to prematurely 
differentiate, and change the pattern of myelination in the developing central 
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nervous system whereas chronic exposure to therapeutic doses of buprenorphine 
on oligodendrocytes and myelination of the central nervous system has not been 
as thoroughly studied. It would be interesting to examine the conduction velocity 
of large diameter myelinated fibers with decreased myelin sheath thickness 
following chronic prenatal and postnatal exposure to therapeutic doses of 
buprenorphine and the conduction velocity of axons with compact myelin following 
chronic prenatal and postnatal exposure to therapeutic doses of methadone which 
have actually not been studied to date. Other future studies should be geared 
towards bridging the gap between changes in the developing central nervous 
system following chronic methadone or buprenorphine exposure and changes in 
neurobehavioral outcomes. Newborn and early childhood neurobehavioral 
outcomes following repeated exposure to methadone or buprenorphine in utero 
are not well understood, are complicated by polysubstance exposure, a deprived 
rearing environment, and dysfunctional parents, and clearly warrant further 
research and longitudinal studies. 
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